FOR IMMEDIATE RELEASE CvilleBioHub Releases 2025 Annual Report Highlighting Breakthrough Year for Regional Life Sciences Innovation Charlottesville, VA — May 5, 2026: CvilleBioHub today announced the release of its 2025...

FOR IMMEDIATE RELEASE CvilleBioHub Appoints Nikki Hastings as President, Marking New Phase of Growth and Regional Leadership Charlottesville, VA — March 26, 2026: CvilleBioHub today announced that its Board of...

California approval opens the door for broad commercial adoption across the state’s diverse specialty crops, with new research confirming strong performance in premium wine grape production CHARLOTTESVILLE, Va. & SAN...

Liquet™ Medical Receives Second FDA 510(k) Clearance for Versus™ Catheter: Expands Hemodynamics-Led Thrombolysis (HLT) Platform and Unlocks New Interventional Segment. Charlottesville, VA – February 24, 2026 Liquet Medical Inc., a...

FOR IMMEDIATE RELEASE Central Virginia Biosciences Employment Grows by 23%  CvilleBioHub Releases GO Virginia–Funded Talent Strategy to Prepare Workforce for Next Wave of Pharmaceutical Manufacturing Growth Charlottesville, VA — March...

Accelerating Discovery: CvilleBioHub’s Commonwealth BioAccelerator Launch at North Fork! From Vision to Reality: Celebrating a Biotech Milestone Against the backdrop of a beautiful warm February evening, the ceremonial ribbon was cut...

GO Virginia, University of Virginia, Manning Family Foundation, and local Economic Development support the three-year project driving life sciences entrepreneurship. Charlottesville, VA (January 14, 2025) — The biotechnology and innovation...

Jazz Pharmaceuticals, a global biopharmaceutical company dedicated to developing life-changing medicines for people with limited or no options, acquired Cavion, Inc., a Charlottesville, VA and Cambridge, MA-based clinical-stage biotechnology company.

Direct Spinal Therapeutics, Inc., a local biotech company, has earned the ninth investment from UVA Licensing and Ventures Group Seed Fund.

HemoShear Therapeutics, a company focused on discovering and developing drugs for metabolic disorders, recently appointed Kathleen M. Metters, PhD, to its board of directors.